Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2024-11-19 M&A Activity
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Grifols informa que el Consejo de Administración no recomendaría a los accionistas de la Sociedad la aceptación de una potencial oferta al precio indicado.
M&A Activity Classification · 100% confidence The document is a formal communication from Grifols, S.A. regarding a potential takeover offer from Brookfield. It explicitly discusses the board's evaluation of the offer, concluding that it undervalues the company and that the board would not recommend it to shareholders. This falls under the category of merger and acquisition activity, specifically a response to a takeover bid. Q4 2024
2024-11-19 Spanish
FORM 6-K
Regulatory Filings
2024-11-19 English
En relación con la nota de información privilegiada enviada hoy a la CNMV por Brookfield, Grifols informa que su Consejo de Administración se reunirá de forma extraordinaria esta tarde para analizar l
Investor Presentation Classification · 95% confidence The document is a formal communication from Grifols, S.A., explicitly labeled as "INFORMACIÓN PRIVILEGIADA" (Inside Information/Privileged Information) and referencing compliance with Spanish securities law (art. 226 of the Consolidated Text of the Securities Market Law). It discusses a potential takeover bid valuation from Brookfield Capital Partners and the Board's preliminary negative assessment of that valuation. This type of communication, dealing with material, non-public information that could significantly affect the share price, is typically classified as a general regulatory disclosure or inside information disclosure. Since there is no specific category for 'Inside Information Disclosure' and it is not an earnings release (ER), management discussion (MDA), or a specific transaction report (like M&A/TAR), the most appropriate fallback category for a significant, mandatory regulatory announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS). The document length is short (2030 chars), but it is the primary disclosure itself, not an announcement *about* a report, so RPA is not appropriate.
2024-11-19 Spanish
Brookfield Capital Partners UK Limited comunica información sobre noticias publicadas en medios de comunicación.
M&A Activity Classification · 100% confidence The document is a formal communication dated November 19, 2024, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - the Spanish securities market regulator). The content explicitly discusses 'INFORMACIÓN PRIVILEGIADA' (Inside Information) regarding a potential takeover offer for Grifols, S.A. It details non-binding indicative values (€10.50 per Class A share) and confirms ongoing due diligence interactions. This type of disclosure, mandated by regulators when rumors surface about a potential M&A transaction, falls under the category of major corporate actions or transactions. Given the specific focus on a potential takeover bid ('potencial oferta'), the most appropriate classification is M&A Activity (TAR). It is not a general regulatory filing (RNS) because it addresses a specific M&A event, nor is it a standard earnings release or report.
2024-11-19 Spanish
13G
Major Shareholding Notification
2024-11-14 English
FORM 6-K
Regulatory Filings
2024-11-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.